Stay updated with breaking news from Elmia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Unprecedented industry milestones achieved with continuous innovation supporting the digital transformation of life sciences SINGAPORE, March 3, 2023 /PRNewswire/ Known for its ground-breaking technological innovations in clinical trials, Medidata, a Dassault Systmes company, has exceeded 30,000 clinical trials and 9 million study participants. These milestones, achieved together with more than 2,100 global customers and partners, have been fueled by Medidata's platform and life sciences solutions that power smarter treatments and healthier people, while driving greater access to trials. "As a patient advocate and study participant, I understand the significance of these milestones," said Anne Marie Mercurio, research advocate and Medidata Patient Insights Board Chair. "And beyond the numbers and the data, Medidata's ongoing commitment to infusing the patient voice into trial designs and solutions, is helping to create a better and more inclusive experience fo ....
On 21 October, Dassault Systmes launched its inaugural hybrid format of the 3DEXPERIENCE Forum Asia Pacific South 2022 In-person roundtable sessions were held across eight cities in five countries, culminating in a virtual edition on 7 December Over 250 business leaders and technologists attended in-person discussions on building resiliency for sustainable success through virtual twin technologies Participants discussed digital transformation and sustainability for the Manufacturing and Mining sectors, as well as the building, planning and running of Infrastructure & Cities SINGAPORE, Dec. 7, 2022 /PRNewswire/ Dassault Systmes(Euronext Paris: FR0014003TT8, DSY.PA) today held the final and virtual edition of its inaugural hybrid 3DEXPERIENCE Forum Asia Pacific South 2022 events. Themed 'Building Resiliency for Sustainable Success with Virtual Twin Experiences', the hybrid Forum also featured an in-person edition attended by over 250 business leaders and technologists, which ....
Seoul [South Korea], November 15 (ANI/PRNewswire): Medidata, a Dassault Systemes company, today announced that C&R Research, the largest Korean CRO, selected Medidata's clinical operation and management solutions 'Rave CTMS (Clinical Trial Management System)' and 'Rave eTMF (electronic Trial Master File)' for their clinical trials. This partnership will reinforce C&R Research's capability to adapt to the fast-paced clinical research environment to monitor clinical operations and comprehensively manage data. Rave CTMS is interconnected with Rave EDC to optimize clinical operations, eliminating manual data re-entry and enabling user-centric workflows that bridge applications. Intelligent automation and workflow management will enhance efficiency and expedite a site monitoring process. All the CTMS data is integrated with eTMF, which can track the necessary information, such as milestones and tasks for each site, in one place, and data entered once and used ....
Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew partnership, further expanding services to Novotech clients in APAC and the US SINGAPORE, June 16, 2022 /PRNewswire/ Medidata, a Dassault Systmes company, today announced its renewed, expanded partnership with Novotech, a leading contract research organisation (CRO), to continue scaling clinical studies in various therapeutic areas from 2022. Leveraging Rave EDC, Rave RTSM, eCOA and eConsent technology from Medidata, Novotech is equipped with flexible, configurable tools that can address clinical research needs at scale and facilitate accelerated drug and device development in Asia Pacific and the U.S. Since its partnership in 2018, Novotech has doubled its growth and has also acquired CRO companies in APAC and the U.S. as well as invested in advanced DCT and data companies to deliver a seamless CRO platform amidst the increasing demand for clinical trials services in the region. The partnership extends access to ....